Stephen K. Brannan - 01 Mar 2022 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Medical Officer
Signature: /s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Mar 2022
Net transactions value: -$745,110
Form type: 4
Filing time: 02 Mar 2022, 16:52:22 UTC
Previous filing: 17 Feb 2022
Next filing: 04 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$13,625	+2,500	+25%	$5.45^*	12,500	01 Mar 2022	Direct
transaction	KRTX	Common Stock	Options Exercise	$71,098	+7,728	+62%	$9.20^*	20,228	01 Mar 2022	Direct
transaction	KRTX	Common Stock	Sale	$829,833	-7,728	-38%	$107.38	12,500	01 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-2,500	-6.1%	$0.000000	38,704	01 Mar 2022	Common Stock	2,500	$5.45	Direct	F2
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-7,728	-11%	$0.000000	59,989	01 Mar 2022	Common Stock	7,728	$9.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2021.
F2	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F3	This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of March 21, 2019.